Arvinas (NASDAQ:ARVN) CEO Sells $95,990.58 in Stock

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 9,657 shares of Arvinas stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $95,990.58. Following the completion of the transaction, the chief executive officer owned 287,218 shares in the company, valued at $2,854,946.92. This trade represents a 3.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Randy Teel also recently made the following trade(s):

• On Monday, February 23rd, Randy Teel sold 4,786 shares of Arvinas stock. The shares were sold at an average price of $12.16, for a total value of $58,197.76.
• On Friday, February 13th, Randy Teel sold 4,403 shares of Arvinas stock. The shares were sold at an average price of $11.89, for a total value of $52,351.67.

Arvinas Trading Down 3.6%

Shares of ARVN stock opened at $9.08 on Friday. The business’s 50 day moving average is $10.97 and its two-hundred day moving average is $11.67. Arvinas, Inc. has a twelve month low of $6.05 and a twelve month high of $14.51. The company has a market capitalization of $585.84 million, a P/E ratio of -2.73 and a beta of 1.79.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.05. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The firm had revenue of $15.60 million for the quarter, compared to the consensus estimate of $16.61 million. During the same period in the previous year, the business earned $1.14 earnings per share. The company’s revenue for the quarter was down 91.7% compared to the same quarter last year. As a group, equities analysts predict that Arvinas, Inc. will post -2.85 earnings per share for the current fiscal year.

More Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a Buy rating, signaling continued Wall Street confidence in upside potential. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer’s breast cancer drug vepdegestrant was licensed to Rigel Pharmaceuticals in a deal that includes $85 million upfront and up to $320 million in milestones, which supports the value of Arvinas’ PROTAC platform and adds potential non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas’ breast cancer drug
• Neutral Sentiment: HC Wainwright modestly adjusted several earnings forecasts for Arvinas, including lower estimates for 2026-2029 and a small cut to FY2030 EPS, reflecting ongoing uncertainty around future profitability rather than a major new development.
• Neutral Sentiment: Arvinas recently beat Q1 EPS estimates, but revenue missed expectations and dropped sharply year over year, reinforcing that the company remains far from sustained profitability. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Recent insider selling by the CEO, CFO, CAO, and another executive may be pressuring sentiment, even though the sales were disclosed as tax-withholding transactions tied to equity vesting. CEO insider filing

Analysts Set New Price Targets

A number of research firms recently weighed in on ARVN. Truist Financial set a $10.00 price target on Arvinas in a research note on Wednesday, March 18th. Barclays lifted their price target on Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday. Wedbush lifted their price target on Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. BTIG Research lifted their price target on Arvinas from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Citigroup lifted their price target on Arvinas from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, May 4th. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Arvinas currently has a consensus rating of “Hold” and an average price target of $14.69.

Institutional Trading of Arvinas

Several institutional investors and hedge funds have recently bought and sold shares of ARVN. Tower Research Capital LLC TRC lifted its stake in Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after purchasing an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of Arvinas by 109.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after buying an additional 3,500 shares in the last quarter. State of Wyoming purchased a new stake in shares of Arvinas during the 3rd quarter valued at $68,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Arvinas during the 3rd quarter valued at $92,000. Finally, Jain Global LLC purchased a new stake in shares of Arvinas during the 3rd quarter valued at $95,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.